Digital healthcare company Emocog has signed a three-year exclusive domestic sales and marketing agreement with Daewoong Pharmaceutical for Cogthera, a physician-prescribed digital therapeutic for mild cognitive impairment (MCI), and Cogscreen, a digital memory test. The companies will use Daewoong's nationwide medical-institution network to connect early screening with physician-led treatment. Cogthera surpassed 2,000 cumulative prescriptions in August, about 10 months after its first prescription in October last year. Emocog said 99.3% of patients in a real-world data group began training after prescription, while repeat prescriptions represented about 21% of cumulative prescriptions, rising from 13% in the first 1,000 prescriptions to 30% in the second 1,000. Daewoong will begin full-scale sales and marketing on Oct. 1, while Emocog will handle product supply, quality control, technical support, software upgrades, regulatory approvals and patient support.